Provides laboratory testing and test-development services to life sciences and biotechnology companies. Develops molecular diagnostic tests and kits for hospitals, transplant centers, laboratories and researchers.
10-K for FY2025, filed Mar 26, 2026We also perform other assay development and clinical testing services for life sciences and biotechnology companies through our Laboratory…View ↗
We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the…View ↗
Our current intellectual property portfolio comprises three general areas: 1) organ transplant, 2) oncology therapy selection, and 3)…View ↗
Laboratory Services brings in fees from life sciences customers for assay development, testing and clinical-trial support; services or tests are usually billed when completed, while some customized projects are billed as work progresses. Research-use kits are sold as goods, with revenue counted when they transfer to customers.
10-K for FY2025, filed Mar 26, 2026Revenues recognized include Laboratory Services performed by iMDx for life sciences customers, including testing for biomarker discovery…View ↗
Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services…View ↗
Revenues recognized include our GraftAssureIQ RUO kitted tests, which are clearly labeled and intended for research purposes. GraftAssureIQ…View ↗
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗$4.1M
10-K for FY2025, filed Mar 26, 2026
$4.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Laboratory Services
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
99% |
Laboratory Services, FY2025
$4M Sources
|
Sold outright |
|
Laboratory Developed Test Services
|
0.0% |
Laboratory Developed Test Services, FY2025
$0 Sources
|
|
|
Kitted Products
Sold outright
|
0.6% |
Kitted Products, FY2025
$24K Sources
|
Sold outright |
Laboratory Services customers are life sciences and biotechnology companies; the company targets hospitals, transplant centers and labs for its molecular tests.
10-K for FY2025, filed Mar 26, 2026
10-K for FY2025, filed Mar 26, 2026
Years EndedDecember 31, 2025 2024 Company A 99 % 84 % Company B * *View ↗
No. It lost $50.2M in FY2025.
Growing. Revenue grew 84% in 4 years, from $2.2M in FY2021 to $4.1M in FY2025, about 17% a year.
Transplant takes priority
The older report described oncology and transplant development programs; the latest makes organ transplant the primary near-term market and describes oncology as secondary, with minimal resources and no near-term commercialization plans.
10-K for FY2022, filed Apr 12, 2023 10-K for FY2025, filed Mar 26, 2026
Transplant kits advance
The older report described VitaGraft lab testing and planned a research-use kit; the latest describes research and clinical GraftAssure kits, and reports sales of GraftAssureIQ to a research laboratory customer.
10-K for FY2022, filed Apr 12, 2023 10-K for FY2025, filed Mar 26, 2026Our current intellectual property portfolio comprises three general areas: 1) organ transplant, 2) oncology therapy selection, and 3)…View ↗
GraftAssureDx – The IVD kit currently in development for use in clinical decision-making.View ↗
Our GraftAssure family of assays are performed on a digital PCR instrument that is manufactured by Bio-Rad Laboratories, Inc. (“Bio-Rad”).…View ↗
Competes with CareDx, Natera, Transplant Genomics, Omixon, and Devyser
10-K for FY2025, filed Mar 26, 2026Our organ transplant rejection monitoring tests compete with other methods of assessing graft organ health, such as performing a manual…View ↗
Loading...